Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
McKinsey
Moodys
Dow
Baxter

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

VENTAVIS Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Ventavis patents expire, and when can generic versions of Ventavis launch?

Ventavis is a drug marketed by Actelion Pharms Ltd and is included in one NDA.

The generic ingredient in VENTAVIS is iloprost. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the iloprost profile page.

Drug patent expirations by year for VENTAVIS
Drug Prices for VENTAVIS

See drug prices for VENTAVIS

Recent Clinical Trials for VENTAVIS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
ActelionPhase 4
National Cancer Institute (NCI)Phase 1
Meshalkin Research Institute of Pathology of CirculationPhase 2

See all VENTAVIS clinical trials

Pharmacology for VENTAVIS
Drug ClassProstacycline
Synonyms for VENTAVIS
(16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2)
(16R,S)-methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I2
(1S,2R,3R,5S)-7-[(E)-4-Carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-bicyclo[3.3.0]octane
(1S,2R,3R,5S)-7-[(E)-4-carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyl-oct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]pentanoic Acid
(5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-ynyl]-2(1H)-pentalenylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-4-[(E,3S)-4-methyl-3-oxidanyl-oct-1-en-6-ynyl]-5-oxidanyl-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyl-oct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid
(E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
(Z)-5-((3aS,4R,5R,6aS)-5-hydroxy-4-((3S,E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid
[3H]-Iloprost
5-((3aS,5R,6aS,E)-5-hydroxy-4-((3S,E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid
5-[(2E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic acid
73873-87-7
78919-13-8
A839531
AC1NSK5T
AC1O5JP3
AC1Q1J28
AKOS024456922
AN-10394
AN-36592
BAY Q6256
BAY-q-6256
BDBM23954
BRD-A45664787-001-01-4
BRD-A45664787-001-02-2
C22H32O4
CAS-78919-13-8
CHEBI:63916
CHEMBL494
Ciloprost
CS-5586
D02721
DB01088
DSSTox_CID_21046
DSSTox_GSID_41046
DSSTox_RID_79616
DTXSID2041046
Endoprost
GTPL1895
HIFJCPQKFCZDDL-ACWOEMLNSA-N
HMS2090A19
HY-A0096
Ilomedin
Ilomedine
ILOPROST
Iloprost (USAN/INN)
Iloprost [BAN:INN]
Iloprost [USAN:INN:BAN]
Iloprost, >=98% (HPLC)
Iloprostum
Iloprostum [Latin]
J-502615
K395
LS-101845
MolPort-023-276-312
NCGC00181784-01
PDSP2_001536
Pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-
SCHEMBL4357
SCHEMBL6083382
SH-401
SR-05000001498
SR-05000001498-1
SR-05000001498-2
Tox21_113586
Ventavis (TN)
ZK 00036374
ZK 36374
ZK-00036374
ZK-36374

US Patents and Regulatory Information for VENTAVIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd VENTAVIS iloprost SOLUTION;INHALATION 021779-002 Dec 8, 2005 RX Yes Yes   Start Trial   Start Trial   Start Trial
Actelion Pharms Ltd VENTAVIS iloprost SOLUTION;INHALATION 021779-001 Dec 29, 2004 DISCN No No   Start Trial   Start Trial   Start Trial
Actelion Pharms Ltd VENTAVIS iloprost SOLUTION;INHALATION 021779-003 Aug 7, 2009 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Merck
Dow
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.